A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.

This is a trial to evaluate the efficacy, safety, and tolerability of HS-10370 in combination with Platinum-based Doublet Chemotherapy With or Without Adebrelimab Versus Tislelizumab Plus Platinum-based Doublet Chemotherapy as first-line treatment in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Start Date31 Oct 2026

Sponsor / Collaborator

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

NCT07789379

/ Not yet recruitingPhase 2IIT

A Prospective, Randomized, Open-Label, Multicenter Phase II Study of Adebrelimab Combined With Temozolomide With or Without Hyperbaric Oxygen Therapy for Newly-Diagnosed Primary Glioblastoma

This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will be enrolled. Subjects will be randomized 1:1 into Arm A (Adebrelimab + Temozolomide + Hyperbaric Oxygen Therapy) or Arm B (Adebrelimab + Temozolomide). The primary endpoint is progression-free survival(PFS). Secondary endpoints include overall survival(OS), objective response rate(ORR), disease control rate(DCR), change of KPS score, safety including TRAE, irAE and SAE. Exploratory objectives include correlation analysis between baseline clinical characteristics / hyperbaric-oxygen-related biomarkers and efficacy-safety outcomes.

Start Date01 Oct 2026

Sponsor / Collaborator-

NCT07811375

/ Not yet recruitingPhase 2IIT

A Single-Center, Single-Arm, Phase II Study of Perioperative Adebrelimab Combined With Neoadjuvant Paclitaxel and Platinum Chemotherapy in Locally Advanced Cervical Cancer

This prospective, single-center, single-arm, phase II study will evaluate perioperative adebrelimab in patients with locally advanced cervical cancer. Approximately 35 participants will receive three 3-week cycles of neoadjuvant adebrelimab in combination with paclitaxel and cisplatin or carboplatin. Participants without disease progression who are considered resectable will undergo radical hysterectomy and pelvic lymph node dissection 28-42 days after the last cycle of neoadjuvant treatment.
Postoperative treatment will be risk-adapted according to pathological risk factors. Participants with high-risk pathological factors will discontinue protocol treatment and receive standard concurrent chemoradiotherapy. Participants with intermediate-risk factors will receive guideline-recommended pelvic radiotherapy plus adebrelimab maintenance, whereas low-risk participants will receive adebrelimab maintenance. Adebrelimab maintenance will be administered every 3 weeks for up to 1 year and may be discontinued early after two consecutive negative circulating tumor HPV DNA tests at least 3 months apart.
The primary endpoint is the pathologic complete response rate. Secondary endpoints include objective response rate, disease control rate, disease-free survival, 2-year disease-free survival rate, overall survival, duration of response, quality of life, and safety. Dynamic circulating tumor HPV DNA will also be explored as a biomarker of treatment response and postoperative recurrence risk.

Start Date01 Oct 2026

Sponsor / Collaborator

Anhui Provincial Hospital

100 Clinical Results associated with Adebrelimab

100 Translational Medicine associated with Adebrelimab

100 Patents (Medical) associated with Adebrelimab

Literatures (Medical) associated with Adebrelimab

31 Dec 2026·Future Science OA

Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?

Article

Author: Wu, Li-Peng ; Liu, Li ; Liu, Tao ; Min, Jie ; Xi, Heng ; Sun, Si-Qin

AIM:

To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.

OBSERVATION:

A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.

CONCLUSION:

This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.

01 Aug 2026·ANNALS OF SURGICAL ONCOLOGY

Laparoscopic Extended Left Hepatectomy and Portal Vein Thrombectomy for Advanced Hepatocellular Carcinoma After Second-Line Conversion Therapy

Article

Author: Wei, Jinxing ; Chen, Yajin ; Zhong, Jinyi ; Tan, Wenliang ; Luo, Xuan ; Zhou, Rui ; Shang, Changzhen

BACKGROUND:

Hepatocellular carcinoma with portal vein tumor thrombus (HCC-PVTT) is correlated with poor prognosis.¹ Recent advances in first-line therapies have enabled some patients with HCC-PVTT to become candidates for curative resection.^2,3 However, over 50% of patients experience disease progression during initial treatment,⁴ and subsequent second-line options remain limited. Furthermore, reports on radical resection in patients with HCC-PVTT after second-line therapy are scarce. Herein, this case highlights the successful downstaging of HCC-PVTT with second-line therapy, followed by laparoscopic hepatectomy and portal vein thrombectomy.

METHODS:

A 56-year-old patient with HCC-PVTT involving the main and left portal veins initially received camrelizumab, apatinib, and systemic FOLFOX (oxaliplatin, fluorouracil, leucovorin).⁵ After 3 cycles, the PVTT progressed to the right portal vein. The multidisciplinary team recommended switching to second-line therapy with regorafenib, adebrelimab, and hepatic arterial infusion chemotherapy.

RESULTS:

The patient experienced progression after first-line therapy (tumor enlargement, PVTT extension), and second-line therapy achieved notable shrinkage of both the tumor and the PVTT. After 5 cycles, surgical resection was feasible. Laparoscopic extended left hepatectomy with portal vein thrombectomy was completed in 340 minutes, with 100 mL blood loss. Pathology revealed HCC with extensive necrosis. Postoperative regorafenib and adebrelimab was administered for 3 cycles, and the patient remains recurrence free to date.

CONCLUSION:

This case report highlights that, for patients with HCC-PVTT with first-line therapy resistance, actively applying second-line therapy can still yield an opportunity for radical resection. It also suggests the feasibility of laparoscopic extended hepatectomy with thrombectomy, emphasizing the value of individualized, multidisciplinary strategies for improving outcomes in complex HCC cases.

01 May 2026·International Journal of Surgery

Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2− early breast cancer: an exploratory study

Article

Author: Xiao, Min ; Ren, He ; Liu, Tong ; Lei, Bo ; Han, Xinhao ; Wang, Jinsong ; Zhang, Crystal Song ; Huang, Fanxuan

Background::

Hormone receptor–positive (HR + )/HER2 − breast cancer (BC) exhibits limited sensitivity to neoadjuvant chemotherapy, with low pathologic complete response (pCR) rates. While CDK4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have demonstrated efficacy, the immunogenicity of HR + /HER2 − tumors remains low, limiting the benefit of immunotherapy. Emerging evidence suggests potential synergy between CDK4/6 inhibition and immune checkpoint blockade. This study explores the neoadjuvant combination of adebrelimab, dalpiciclib, and endocrine therapy in patients with stage II–III HR + /HER2 − BC.

Methods::

This single-arm, exploratory study enrolled postmenopausal women with histologically confirmed stage II–III HR + /HER2 − BC. Eligible patients received neoadjuvant therapy comprising adebrelimab (1200 mg intravenously, day 1), dalpiciclib (125 mg orally, once daily on days 1–21), and letrozole. Treatment was administered over five 28-day cycles prior to surgery. The primary endpoint was total pCR (tpCR; defined as ypT0-is/ypN0).

Results::

Between October 2024 and March 2025 patients (median age 61.5 years) with stage II–III HR + /HER2 − BC were enrolled. Most patients had T2 tumors (85%) and N1 disease (55%). All patients received ≥1 treatment cycle; 17 completed surgery. Radiological partial response was observed in 13 patients (65%), with an overall objective response rate (ORR) of 65%. One patient (5%) achieved tpCR. Three patients discontinued due to adverse events (AE; one death, one hepatitis, and one pneumonia). Common grade ≥ 3 AEs included neutropenia (50%), leukopenia (25%), and elevated liver enzymes.

Conclusion::

This triplet regimen demonstrated modest clinical activity in HR + /HER2 − early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.

News (Medical) associated with Adebrelimab

14 Sep 2026

·www.hspharm.com

WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC

- HS-10370 plus adebrelimab and chemotherapy demonstrated promising anti-tumor activity as first-line therapy for KRAS G12C-mutated advanced NSCLC, with a confirmed ORR of 81.5%; median PFS was not reached, and the 12-month PFS rate was 78.7%. The combination regimen was generally well tolerated. - Patients with advanced KRAS G12C-mutated NSCLC continue to face a poor prognosis and lack targeted first-line options. These findings support further development of the HS-10370 combination regimen as a potential new first-line treatment for this population. - HS-10370 plus adebrelimab and chemotherapy demonstrated promising anti-tumor activity as first-line therapy for KRAS G12C-mutated advanced NSCLC, with a confirmed ORR of 81.5%; median PFS was not reached, and the 12-month PFS rate was 78.7%. The combination regimen was generally well tolerated. - Patients with advanced KRAS G12C-mutated NSCLC continue to face a poor prognosis and lack targeted first-line options. These findings support further development of the HS-10370 combination regimen as a potential new first-line treatment for this population. SHANGHAI, Sep 14, 2026— Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma,” 03692.HK) today announced that HS-10370 combination regimen has yielded encouraging results in patients with untreated advanced KRAS G12C-mutated NSCLC.The results were delivered as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC 2026), held in Seoul, South Korea, from September 12 to 15. HS-10370 is a selective, covalent and orally bioavailable KRAS G12C inhibitor under clinical development for the treatment of patients with advanced KRAS G12C-mutated NSCLC. Preliminary results of the HS-10370-102 study (NCT06594874), which evaluated HS-10370 combined with adebrelimab plus platinum‑based chemotherapy, were disclosed at WCLC 2026. HS-10370-102 is an open‑label, multicenter, phase Ib study for untreated advanced KRAS G12C-mutated NSCLC patients. Eligible patients received HS-10370 at 400 mg or 800 mg once daily orally , combined with adebrelimab plus platinum chemotherapy every 3 weeks intravenously. Treatment continued until disease progression or intolerable toxicity. Key study endpoints included safety, tolerability, ORR and PFS assessed by the investigator per RECIST v1.1 criteria. The study results showed: Robust Anti-tumor Activity: With median follow-up of 13.6 months, The confirmed ORR was 81.5% and the disease control rate (DCR) was 98.1%. Median PFS has not yet reached, and the 12‑month PFS rate was 78.7%. The combination regimen demonstrated consistent antitumor activity across different PD‑L1 expression subgroups. Notably, patients with PD‑L1 TPS ≥ 50% achieved a confirmed ORR of 93.8% and12‑month PFS rate of 100%. Manageable safety profile: Grade ≥3 treatment-related adverse event (TRAEs) occurred in 80.0% of subjects and there were no treatment-related deaths. The permanent discontinuation rate of full study treatments due to TRAEs was only 5.5%, suggesting that most toxicities could be managed with supportive care and dose adjustments without long‑term treatment interruption. The most common TRAEs were hematologic toxicities and liver enzyme elevations, consistent with the known safety characteristics of each individual agent; no unexpected new safety risks were observed with this combination regimen. These compelling efficacy and safety results support advancing this combination into a phase 3 trial to further investigate its value as first-line therapy for patients with KRAS G12C-mutated NSCLC. Details of the oral presentation are as follows: Title: Efficacy and Safety of HS-10370 Combined with Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC Session:OA12. Beyond KRAS: Emerging Targets, Smarter Therapies Abstract No.: 436 Date/Time: Monday, September 14, 2026, 5:00-6:15 PM KST (5:22 PM -5:32 PM) Presenter: Fan Tong, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology About HS-10370 HS-10370 is a highly selective small-molecule inhibitor of the KRAS G12C mutant. Through irreversible targeted covalent binding to the cysteine residue of the KRAS G12C mutant, it locks KRAS G12C in an inactive GDP-bound conformation, thereby blocking downstream signal transduction and inhibiting tumor cell proliferation. About KRAS G12C-mutated NSCLC Lung cancer is among the malignancies with the highest incidence and mortality worldwide; in the Chinese population, both its incidence and mortality rank first among all malignant tumors. [1]. Non‑small cell lung cancer (NSCLC) represents the major pathological subtype of lung cancer, accounting for 85%‑90% of all lung cancer cases [2]. According to histopathology, NSCLC is further divided into lung adenocarcinoma and lung squamous cell carcinoma; lung adenocarcinoma accounts for 55%‑60% of all NSCLC [3]. Due to the high invasiveness of NSCLC and the fact that early‑stage NSCLC is often asymptomatic, most patients are diagnosed at an advanced stage [2]. For these advanced‑stage patients, the disease has spread beyond local anatomical boundaries, accompanied by regional lymph node metastasis or distant organ metastasis, and is associated with a short natural disease course with rapid disease progression, which seriously endangers their lives. KRAS gene mutation is one of the most critical oncogenic drivers in NSCLC and is particularly prevalent in lung adenocarcinoma. Among these mutations, the G12C point mutation accounts for approximately 3‑4% of all NSCLC cases and 8‑10% of lung adenocarcinomas. According to data released by the World Health Organization (WHO) in 2020, an estimated 35 000 patients in China were diagnosed with KRAS G12C‑mutated newly‑onset lung cancer in 2020. [4] According to the 2026 NCCN Guidelines and CSCO Guidelines,first-line treatment options for NSCLC with KRAS G12C mutation are identical to those for NSCLC patients without actionable driver mutations, namely immune checkpoint inhibitor combined with platinum‑based doublet chemotherapy.There remains a lack of effective targeted therapeutic agents for first‑line therapy. Although this regimen has achieved remarkable progress, the majority of patients with metastatic NSCLC without actionable gene alterations experience disease progression within 1 year of diagnosis and die from the disease within 3 years [5]. Therefore, there remains an unmet medical need for novel therapies that can further improve treatment response and survival in patients with metastatic NSCLC. References [1]Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74 (3): 229-263. [2]中国抗癌协会肿瘤精准治疗专业委员会中华医学会杂志社肺癌研究协作组. 驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识（2023版）. 中华肿瘤杂志2023, 45(9): 717-740. [3]Chen et al. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022 Oct;42(10):937-970. [4]Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024 Mar 23;46(3):221-231. [5]Pantsar T. The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J. 2020;18:189-98 About Hansoh Pharma Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK). Statements 1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional. Forward-Looking Statements This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).

Clinical ResultPhase 1

03 Sep 2026

·allsci.com

NMPA accepts Hansoh’s B7-H3 ADC HS-20093 in post-platinum SCLC

China's National Medical Products Administration (NMPA) has accepted a biologics license application from Hansoh Pharmaceutical Group Company Limited (HKEX: 03692) for HS-20093, a B7-H3-directed antibody-drug conjugate (ADC), in adult patients with small cell lung cancer (SCLC) who have progressed on prior platinum-based chemotherapy. The filing, accepted September 2, 2026, marks the first regulatory submission for HS-20093 in SCLC. The application follows the Phase III ARTEMIS-008 trial, in which HS-20093 demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with topotecan at a pre-specified interim analysis. Consistent benefit was also reported across secondary endpoints including progression-free survival. Hansoh said the safety profile was consistent with prior findings, with no new signals identified. Detailed data are expected at an upcoming international oncology conference. HS-20093 targets B7-H3 (CD276), an immune checkpoint protein broadly overexpressed across multiple solid tumor types, and delivers a topoisomerase I inhibitor payload following receptor-mediated internalization. The molecule is licensed to GSK outside Greater China. The SCLC filing is the first confirmed BLA submission for HS-20093. Hansoh is also preparing an approval filing in China for HS-20093 in osteosarcoma based on a positive data readout from the ARTEMIS-011 study, which met its primary endpoint of progression-free survival in relapsed or refractory osteosarcoma. The molecule had also received NMPA Breakthrough Therapy Designation in April 2026 in combination with adebrelimab for non-squamous non-small cell lung cancer after platinum-based chemotherapy, extending development of HS-20093 across a third tumor type. In post-platinum SCLC, topotecan remains a standard second-line option despite modest efficacy, while lurbinectedin is available in some markets. No ADC is currently approved in this setting in China. HS-20093’s Phase III survival benefit against topotecan therefore gives Hansoh a clinically differentiated basis for its first regulatory filing for the drug. Spot something wrong? Report an issue with this article

Phase 3ADCClinical ResultBreakthrough TherapyNDA

09 Jul 2026

·synapse.patsnap.com

B7-H3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy

B7-H3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D StrategyThis B7-H3 target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. It turns target biology, disease context, clinical validation, competitive intensity, and IP strategy into a repeatable target evaluation workflow for life sciences AI agents. Explore PatSnap Life Sciences MCP Servers Target B7-H3 UniProt Q5ZPR3 Target-linked drugs 278 254 active development drugs NSCLC trials 29 B7-H3 + NSCLC MCP query Released results 5 Clinical result query Executive ViewB7-H3 / CD276 is an attractive solid-tumor target with strong translational interest and growing clinical competition in non-small cell lung cancer. The target is compelling because it sits at the intersection of tumor immune evasion and antibody-drug conjugate development, but differentiation depends on payload, therapeutic index, patient selection, and evidence in driver-negative or post-standard-care NSCLC. Biology: Target & Disease MCP identifies CD276, also known as B7-H3, as an immune-regulatory molecule that may inhibit NK-mediated tumor-cell lysis and modulate T-cell responses.Disease context: NSCLC is a large oncology development arena with high clinical activity and intense standard-of-care competition.Validation: Clinical Trials MCP returns 29 B7-H3 + Non-Small Cell Lung Cancer trials and 5 released result records.Strategy: Differentiate through ADC design, tumor-expression threshold, safety window, and combination with immunotherapy or chemotherapy.ScorecardBiology confidence: High translational rationale Clinical validation: Emerging-to-medium Competitive pressure: Rising White-space potential: ADC and biomarker-led Biology and Disease RationaleTarget & Disease MCP returns CD276 / B7-H3 with aliases including B7H3 and 4Ig-B7-H3, UniProt Q5ZPR3, and 278 target-linked drugs. The target profile points to immune-response regulation, protection of tumor cells through inhibition of NK-mediated lysis, and modulation of CD4 and cytotoxic T-cell activity. This biology supports both immuno-oncology positioning and B7-H3-directed ADC strategies. For non-small cell lung cancer, Target & Disease MCP shows a highly active disease record with 1,526 development drugs and 2,155 roll-up development drugs. That context means a B7-H3 program needs a clear clinical niche, such as driver-negative disease, post-checkpoint treatment, biomarker-enriched populations, or ADC sequencing after other targeted payload approaches. Explore PatSnap Life Sciences MCP Servers for AI agents Selected Trial and Result EvidenceHS-20093 + adebrelimab vs docetaxelClinical Trials MCP returned not-yet-recruiting Phase 3 studies in driver-gene-negative advanced or metastatic non-squamous NSCLC, showing late-stage competitive movement around B7-H3-directed therapy.IDE034 in locally advanced/metastatic solid tumorsRecruiting Phase 1 study, reflecting broader early clinical exploration of B7-H3-directed modalities across solid tumors.KEYMAKER-U01 substudies in stage IV NSCLCClinical trial result query returned a positive Phase 2 record involving ifinatamab deruxtecan, raludotatug deruxtecan, and docetaxel in stage IV NSCLC.YL-201 B7-H3-targeting ADCReleased Phase 1/1b positive result record in advanced solid tumors, supporting the ADC development thesis for B7-H3.IP and R&D RecommendationB7-H3 IP review should map antibody sequences, ADC linker-payload claims, epitope coverage, dosing and combination claims, NSCLC biomarker thresholds, and freedom-to-operate against established CD276-directed antibody and ADC portfolios. RecommendationB7-H3 is attractive for teams with a differentiated ADC platform or a strong biomarker strategy. In NSCLC, the strongest development story should connect expression-defined enrollment, post-standard-care positioning, payload tolerability, and comparative evidence versus docetaxel or checkpoint-based combinations. Start building target evaluation agents with PatSnap Life Sciences MCP Servers Data note: Target biology, disease profile, clinical trial counts, trial examples, and result evidence were generated from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP queries performed on July 9, 2026.

100 Deals associated with Adebrelimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	23 Jun 2026
Extensive stage Small Cell Lung Cancer	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	28 Feb 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	07 May 2026
Gastroesophageal junction adenocarcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	07 May 2026
Gastrooesophageal junction cancer	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	07 May 2026
Gastrooesophageal junction cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	07 May 2026
Locally Advanced Rectal Carcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	23 Mar 2026
Advanced biliary tract cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	21 Jan 2026
Advanced Cervical Carcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	08 Oct 2025
Locally Advanced Cervical Carcinoma	Phase 3	China	Shanghai Shengdi Pharmaceutical Co., Ltd.	08 Oct 2025
PD-L1 positive Triple Negative Breast Cancer	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	20 Aug 2025
Metastatic Gastroesophageal Junction Adenocarcinoma	Phase 3	China	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	18 Aug 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2026	Not Applicable	Small Cell Lung Cancer First line	6	Adebrelimab + Famitinib + Chemotherapy	qfswpuelkk(btnfppigan) = xjoufcbslv yftiddqaqt (rccgszcyjq ) View more	Positive	12 Sep 2026
NCT06236997 (WCLC2026)	Phase 2	Extensive stage Small Cell Lung Cancer First line	46	Adebrelimab + Chemotherapy + Radiotherapy (Extensive-Stage Small-Cell Lung Cancer)	xchonywgmd(rncssdmpof) = afomhazijl odttkdqkqc (xaxxqkortj ) View more	Positive	12 Sep 2026
NCT06336954 (WCLC2026)	Phase 2	Non-Small Cell Lung Cancer	40	Adebrelimab 1200 mg + Adebrelimab 1200 mg + Adebrelimab 1200 mgaclitaxel 260 mg/m² or docetaxel 60-75 mg/m²)	mayjklvvxr(aiayplxqwl) = reumyyduyg tvnrsbnxwi (icdivpkfxw )	Positive	12 Sep 2026
WCLC2026	Not Applicable	Small Cell Lung Cancer Neoadjuvant	6	Adebrelimab + etoposide + cisplatin	ljnrgnormv(ztunhcbtny) = ximcfwlucw hfayrvazqq (demdppjacl ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Small Cell Lung Cancer Neoadjuvant	51	chemotherapy + Adebrelimab	mvjllrpzsv(etjfovmgcg) = ikhvnmpdtn qtdetltfop (hffdqznlak ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Small Cell Lung Cancer Neoadjuvant	51	chemotherapy	mvjllrpzsv(etjfovmgcg) = liwtgcankd qtdetltfop (hffdqznlak ) View more	Positive	12 Sep 2026
WCLC2026	Phase 2	Locally Advanced Unresectable Carcinoma Neoadjuvant	27	Adebrelimab + Nab-paclitaxel + Carboplatin	efndkdcdoy(ubpuyfliit) = glcrkhxfxq cyfkhswosi (dmszjbcwwq ) View more	Positive	12 Sep 2026
WCLC2026	Phase 2	Resectable Lung Non-Small Cell Carcinoma Neoadjuvant	41	Adebrelimab+Anlotinib+Chemotherapy	cqqrgdxadh(olpapqcery) = membyksjis vmwgfbvcyo (dgsdyvqume ) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Second line	9	SHR-A1921+adebrelimab	nataehsawr(ilkisogxjn) = zqywcwypwx cbethiqeik (ipwkgaowen, 4.8 - NR) View more	Positive	12 Sep 2026
WCLC2026	Not Applicable	Second line	9	SHR-A1921+adebrelimab (squamous NSCLC)	uweguyewsr(nixlpefhhd) = iiicpfvquc mzmuzheiuf (dnbmsskuzr, 4.4 - NR)	Positive	12 Sep 2026
WCLC2026	Phase 2	Small cell lung cancer limited stage Neoadjuvant	40	Adebrelimab + Chemotherapy (3 cycles)	tenemrnsng(dtmduxuchg) = tbfnrnloub qinzhphpza (trtypgvcxq ) View more	Positive	12 Sep 2026
NCT07398560 (CAPSTONE-1, ASCO_Breakthrough2026)	Phase 2	Small Cell Lung Cancer First line	47	Adebrelimab + oral etoposide	mrvcuckpzb(ntkcclxilv) = xjbdxkxrez ditvbxzdhn (tgrundquwh )	Positive	25 Jun 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis